DOCSLIB.ORG

Changes in Gene Expression Under MET-Stress in CAPAN1 and CFPAC1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Changes in Gene Expression Under MET-Stress in CAPAN1 and CFPAC1 Supplement: Changes in gene expression under MET-stress in CAPAN1 and CFPAC1. Significant (<0.05) changes of 2.5 fold or greater that occur in cultures under MET-stress for either CAPAN1 or CFPAC for 4 and 6 d respectively, are listed. NE: not expressed denotes relative expression of less than 200 in both methionine (M) and homocysteine (H) sets. CAPAN1 CAPAN1 CFPAC1 CFPAC1 GENE SYMBOL CHROMOSOME MET HCYS M/H MET HCYS M/H Growth arrest and DNA-damage-inducible, beta GADD45B chr19p13.3 47.4 2605.4 0.02 546.5 978.9 0.56 clusterin CLU chr8p21-p12 31 610.2 0.05 NE cyclin-dependent kinase 5 CDK5 chr7q36 44 502.3 0.09 286.1 628.4 0.46 SMAD, mothers against DPP homolog 7 SMAD7 chr18q21.1 30.1 337.2 0.09 410.8 968.3 0.63 colony stimulating factor 1 (macrophage) CSF1 chr1p21-p13 50.4 487.1 0.10 1105.5 1741.8 0.42 breast cancer 1, early onset BRCA1 chr17q21 31.6 316.5 0.11 125.5 427.1 0.29 TGF, beta receptor associated protein 1 TGFBRAP1 chr2q12.1 72.9 648.9 0.11 NE tuftelin interacting protein 11 TFIP11 chr22q12.1 63.8 561.5 0.11 212.2 382 0.56 three prime repair exonuclease 1 TREX1 chr3p21.3-p21.2 39.8 310.1 0.13 59.5 310.8 0.19 v-ets erythroblastosis virus E26 oncogene homolog2 ETS2 chr21q22.3|21q22.2 105 807.1 0.13 615.9 414.2 1.49 growth differentiation factor 15 GDF15 chr19p13.1-13.2 275 1940.1 0.14 4961.8 6636.5 0.75 c-myc binding protein MYCBP chr1p33-p32.2 32.4 226.8 0.14 448.6 525.5 0.85 protein (peptidyl-prolyl cis/trans isomerase) 1 PIN1 chr19p13 102 683.8 0.15 NE putative lymphocyte G0/G1 switch gene G0S2 chr1q32.2-q41 1485.3 9136.8 0.16 613.6 2458.5 0.25 insulin-like growth factor binding protein 4 IGFBP4 chr17q12-q21.1 185.7 1113.8 0.17 914.2 2643.7 0.35 sphingosine kinase 2 SPHK2 chr19q13.2 139.3 832.8 0.17 62 360.5 0.17 neurofibromin 2 NF2 chr22q12.2 131.7 561.4 0.23 364.6 687.5 0.53 S100 calcium binding protein A3 S100A3 chr1q21 282.3 1167.7 0.24 28.3 389.4 0.07 immediate early response 3 IER3 chr6p21.3 2648.1 10433.2 0.25 17681.9 24362.4 0.73 interferon, gamma-inducible protein 16 IFI16 chr1q22 75.6 271.7 0.28 2023.9 2653 0.76 RAD51 homolog C RAD51C chr17q22-q23 150.7 538.6 0.28 370.3 710.3 0.52 guanine nucleotide binding protein (G protein), GNA11 chr19p13.3 75 265.1 0.28 553.9 639.5 0.87 methionine adenosyltransferase II, alpha MAT2A chr2p11.2 3776.7 12193.4 0.31 1368.7 3525.9 0.39 cyclin-dependent kinase inhibitor 2C (p18) CDKN2C chr1p32 278.4 896.5 0.31 148.2 288.2 0.51 mesenchymal stem cell protein DSC92 NEUGRIN chr15q26.1 1297.6 4097.2 0.32 3687.8 5289.8 0.70 BCL2-associated athanogene 5 BAG5 chr14q32.32 1093.7 3264.9 0.34 1288.2 2283.4 0.56 thioredoxin TXN chr9q31 3013.3 8415 0.36 3363.2 3120.3 1.08 BCL2-associated athanogene 3 BAG3 chr10q25.2-q26.2 619.8 1660.3 0.37 857.3 1565.7 0.55 BH3 interacting domain death agonist BID chr22q11.1 1192.2 2777.6 0.43 640.1 1499.7 0.43 Interferon-related developmental regulator 1 IFRD1 chr7q22-q31 700.9 1189.4 0.43 272.4 391.1 0.70 IFN-induced protein with tetratricopeptide repeats 2 IFIT2 chr10q23-q25 326.8 708.8 0.46 255.4 1164.5 0.22 superoxide dismutase 2, mitochondrial SOD2 chr6q25.3 388.7 756.8 0.51 361.8 1400.3 0.26 cyclin D1 CCND1 chr11q13 792 1404.2 0.56 1037 1319.3 0.79 interferon gamma receptor 1 IFNGR1 chr6q23-q24 981.4 1709.7 0.57 1202.5 3844.9 0.31 interferon regulatory factor 1 IRF1 chr5q31.1 852.1 1284.2 0.66 1203.4 2996.9 0.40 interleukin 8 IL8 chr4q13-q21 1617.3 2385.2 0.68 4411.3 12319.5 0.36 intercellular adhesion molecule 1 (CD54), ICAM1 chr19p13.3-p13.2 480.7 674.7 0.71 412.1 1477.3 0.28 TGFB inducible early growth response TIEG chr8q22.2 1195.6 1670.1 0.72 2002.6 4534.4 0.44 pentaxin-related gene, rapidly induced by IL-1 beta PTX3 chr3q25 2866.7 3983.7 0.72 138.8 523.2 0.27 BCL2-antagonist of cell death BAD chr11q13.1 646.4 889.9 0.73 594.7 963.9 0.62 BCL2-antagonist/killer 1 BAK1 chr6p21.3 525.2 708.7 0.74 640.9 857.1 0.75 2'-5'-oligoadenylate synthetase 3, 100kDa OAS3 chr12q24.2 486.6 587.5 0.82 730.5 1087 0.67 colony stimulating factor 3 (granulocyte) CSF3 chr17q11.2-q12 705.7 857.9 0.82 64.5 324.7 0.20 Rho guanine nucleotide exchange factor (GEF) 12 ARHGEF12 chr11q23.3 747.9 901.6 0.83 NE BRCA1 associated protein-1 BAP1 chr3p21.31-p21.2 817.5 952.8 0.86 276.7 1112 0.25 pim-2 oncogene PIM2 chrXp11.23 522.2 504 1.04 347.6 1239.8 0.28 cell division cycle 25B CDC25B chr20p13 1442.2 1110.4 1.30 1201.3 3222.9 0.37 epidermal growth factor receptor EGFR chr7p12 928.5 694.4 1.34 430 89.4 4.81 ribonuclease H1 RNASEH1 chr2p25 1011 697.6 1.45 539.4 173.4 3.11 insulin induced gene 1 INSIG1 chr7q36 519.4 310.6 1.67 1351.6 42.1 32.11 early growth response 3 EGR3 chr8p23-p21 679.9 375.6 1.81 NE WEE1 homolog (S. pombe) WEE1 chr11p15.3-p15.1 463.7 201.2 2.30 709.4 606.6 1.17 cyclin A2 CCNA2 chr4q25-q31 219.6 78.5 2.80 239.1 187.8 1.27 serum/glucocorticoid regulated kinase SGK chr6q23 13360 4694.5 2.85 1025.6 4,409.4 0.23 glutaminyl-tRNA synthetase QARS chr3p21.3-p21.1 2069.9 688.5 3.01 2341.6 1604.1 1.46 early growth response 1 EGR1 chr5q31.1 1305.6 424.9 3.07 2177.1 1297.5 1.68 excision repair cross-complement repair deficiency ERCC1 chr19q13.2-q13.3 3856.8 1250.7 3.08 514.9 569.4 0.90 BUB1 budding uninhibited by benzimidazoles 1 BUB1 chr2q14 727.9 234 3.11 320 140.6 2.28 CDC42 effector protein (Rho GTPase binding) 3 CDC42EP3 chr2p21 1941.5 621.2 3.13 777.8 539 1.44 cyclin G1 CCNG1 chr5q32-q34 6177.9 1942.6 3.18 2823.1 1893.4 1.49 glucose regulated protein, 58kDa GRP58 chr15q15 1947.6 602.3 3.23 4143.4 1049.2 3.95 nuclear receptor subfamily 4, group A, member 1 NR4A1 chr12q13 469.1 143.4 3.27 394.1 110.1 3.58 mutS homolog 6 MSH6 chr2p16 834.9 251.5 3.32 533.9 480.8 1.11 cyclin B1 CCNB1 chr5q12 1510.3 453.4 3.33 791.5 336.9 2.35 nucleosome assembly protein 1-like 1 NAP1L1 chr12q21.2 11201.2 3338.5 3.36 5557 3470.8 1.60 phospholipase C, beta 3 (phosphatidylinositol- spec.) PLCB3 chr11q13 504.3 150 3.36 316 176.4 1.79 MAD2 mitotic arrest deficient-like 1 (yeast) MAD2L1 chr4q27 523.7 155.2 3.37 514.5 455 1.13 Cell division cycle 2, G1 to S and G2 to M CDC2 chr10q21.1 417 121 3.45 616.1 196.1 3.14 v-jun sarcoma virus 17 oncogene homolog (avian) JUN chr1p32-p31 704.8 203 3.47 4826 2801.6 1.72 deoxyribonuclease I-like 1 DNASE1L1 chrXq28 835.8 237.9 3.51 814 615.7 1.32 poly(A) binding protein, cytoplasmic 4 (inducible) PABPC4 chr1p32-p36 5326.5 1449.6 3.67 3096.1 1613.6 1.92 androgen-induced proliferation inhibitor APRIN chr13q12.3 476.8 128.3 3.72 209.7 72.6 2.89 Ras homolog gene family, member B RHOB chr2p24 2306.3 618.9 3.73 5804.2 4537.3 1.28 stanniocalcin 1 STC1 chr8p21-p11.2 1945.9 511.9 3.80 NE ubiquitin-conjugating enzyme E2C UBE2C chr20q13.12 2190.1 569.5 3.85 1393.4 512.2 2.72 septin 10 10-Sep chr2q13 2733.6 694.7 3.93 NE aurora kinase B AURKB chr17p13.1 824.7 209.1 3.94 296.5 178 1.67 transducin (beta)-like 3 TBL3 chr16p13.3 468.3 115.6 4.05 505.6 572.4 0.88 antigen identified by monoclonal antibody Ki-67 MKI67 chr10q25-qter 143.7 33.6 4.28 308.7 51 6.05 polo-like kinase 1 (Drosophila) PLK1 chr16p12.1 147.8 34.3 4.31 309.9 79.7 3.89 amphiregulin (schwannoma-derived growth factor) AREG chr4q13-q21 2295.2 518.4 4.43 2725.8 822.8 3.31 integrin, beta 4 ITGB4 chr17q25 1707.4 378.2 4.51 3414.5 1444.7 2.36 interferon induced transmembrane protein 1 (9-27) IFITM1 chr11p15.5 1805.8 378.2 4.77 4312.3 5114.2 0.84 Fanconi anemia, complementation group L FANCL chr2p16.1 459.7 95.8 4.80 263.3 230.4 1.14 insulin receptor substrate 2 IRS2 chr13q34 1000 207.1 4.83 2426 1650.5 1.47 protein regulator of cytokinesis 1 PRC1 chr15q26.1 615.6 118.7 5.19 762 252.1 3.023 Cell division cycle 2-like 6 (CDK8-like) CDC2L6 chr6q21 578.7 110.8 5.22 284 255.7 1.11 casein kinase 1, epsilon CSNK1E chr22q13.1 473.3 88.8 5.33 201.3 20.1 10.01 epiregulin EREG chr4q13.3 4513.6 819.3 5.51 2992.5 2074.2 1.44 thymidylate synthetase TYMS chr18p11.32 2251.8 404.7 5.56 360.2 231.7 1.55 serine (or cysteine) proteinase inhibitor, clade A SERPINA3 chr14q32.1 1231.1 216.4 5.69 402.7 1177 0.34 O-6-methylguanine-DNA methyltransferase MGMT chr10q26 336.2 57.8 5.82 404.8 43.3 9.34 high-mobility group box 2 HMGB2 chr4q31 2304.1 353.9 6.51 1129.5 571.2 1.98 tumor protein p73-like TP73L chr3q27-q29 494.9 71.6 6.91 NE nucleolar and spindle associated protein 1 NUSAP1 chr15q15.1 726.2 104.9 6.92 523.5 303 1.73 dual specificity phosphatase 6 DUSP6 chr12q22-q23 525.1 74.2 7.08 2728.5 1441.9 1.89 protein tyrosine phosphatase-like PTPLA chr10p14-p13 722.6 97.1 7.44 505.5 415.3 1.22 dual specificity phosphatase 1 DUSP1 chr5q34 10036.3 1310.4 7.66 21249.1 15608.9 1.36 DNA replication factor CDT1 chr16q24.3 472.1 58.2 8.11 374.7 267.6 1.40 Fanconi anemia, complementation group A FANCA chr16q24.3 617.8 67.8 9.11 254.4 76.4 3.33 Cell division cycle associated 8 CDCA8 chr1p34.3 513.5 55.1 9.32 342.8 61.3 5.59 growth arrest-specific 1 GAS1 chr9q21.3-q22 492.4 47.4 10.39 NE dual specificity phosphatase 2 DUSP2 chr2q11 465.4 44.7 10.41 NE topoisomerase (DNA) II alpha 170kDa TOP2A chr17q21-q22 1280.4 92.3 13.87 1457 748.1 1.95 Kruppel-like factor 6 KLF6 chr10p15 1080.8 51.6 20.95 1037.7 342.7 3.03 kinetochore associated 2 KNTC2 chr18p11.32 809.5 36.4 22.24 NE kinesin family member 20A KIF20A chr5q31 639.7 28.1 22.77 584.5 104.6 5.59 lectin, galactoside-binding, soluble, 1 (galectin 1) LGALS1 chr22q13.1 9930.3 272.8 36.40 602.1 638.4 0.94 cyclin B2 CCNB2 chr15q22.2 1235.3 30.1 41.04 759.6 304.8 2.49 FBJ osteosarcoma viral oncogene homolog B FOSB chr19q13.32 2067.1 41.1 50.29 5175.6 3983 1.30 NIMA (never in mitosis gene a)-related kinase 2 NEK2 chr1q32.2-q41 415.1 5.4 76.87 251.2 26.4 9.52 v-fos FBJ osteosarcoma viral oncogene
Load more

Recommended publications
  • Silencing of Phosphoinositide-Specific
    ANTICANCER RESEARCH 34: 4069-4076 (2014) Silencing of Phosphoinositide-specific Phospholipase C ε Remodulates the Expression of the Phosphoinositide Signal Transduction Pathway in Human Osteosarcoma Cell Lines VINCENZA RITA LO VASCO1, MARTINA LEOPIZZI2, DANIELA STOPPOLONI3 and CARLO DELLA ROCCA2 Departments of 1Sense Organs , 2Medicine and Surgery Sciences and Biotechnologies and 3Biochemistry Sciences “A. Rossi Fanelli”, Sapienza University, Rome, Italy Abstract. Background: Ezrin, a member of the signal transduction pathway (5). The reduction of PIP2 ezrin–radixin–moesin family, is involved in the metastatic induces ezrin dissociation from the plasma membrane (6). spread of osteosarcoma. Ezrin binds phosphatydil inositol-4,5- The levels of PIP2 are regulated by the PI-specific bisphosphate (PIP2), a crucial molecule of the phospholipase C (PI-PLC) family (7), constituting thirteen phosphoinositide signal transduction pathway. PIP2 levels are enzymes divided into six sub-families on the basis of amino regulated by phosphoinositide-specific phospholipase C (PI- acid sequence, domain structure, mechanism of recruitment PLC) enzymes. PI-PLCε isoform, a well-characterized direct and tissue distribution (7-15). PI-PLCε, a direct effector of effector of rat sarcoma (RAS), is at a unique convergence RAS (14-15), might be the point of convergence for the point for the broad range of signaling pathways that promote broad range of signalling pathways that promote the RAS GTPase-mediated signalling. Materials and Methods. By RASGTPase-mediated signalling (16). using molecular biology methods and microscopic analyses, In previous studies, we suggested a relationship between we analyzed the expression of ezrin and PLC genes after PI-PLC expression and ezrin (17-18).
    [Show full text]
  • Effective Angiogenesis Requires Regulation of Phosphoinositide Signaling
    Effective angiogenesis requires regulation of phosphoinositide signaling Elizabeth Michele Davies, Rajendra Gurung, Kai Qin Le, Christina Anne Mitchell* Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia *Corresponding author [email protected] Abstract Phosphoinositide signaling regulates numerous downstream effectors that mediate cellular processes which influence cell cycle progression, migration, proliferation, growth, survival, metabolism and vesicular trafficking. A prominent role for phosphoinositide 3-kinase, which generates phosphatidylinositol 3,4,5-trisphosphate, a phospholipid that activates a plethora of effectors including AKT and FOXO during embryonic and postnatal angiogenesis, has been described. In addition, phosphatidylinositol 3-phosphate signaling is required for endosomal trafficking, which contributes to vascular remodeling. This review will examine the role phosphoinositide signaling plays in the endothelium and its contribution to sprouting angiogenesis. Keywords Angiogenesis, Phosphoinositide, PI3K, PTEN 1. Introduction Establishment of a functional vasculature is essential for embryonic development, and also for the maintenance of tissue regeneration, inflammatory responses and wound healing in the adult. Vascular development is characterized by two distinct physiological processes, vasculogenesis and angiogenesis. Vasculogenesis is predominantly limited to embryonic development, whereby differentiation
    [Show full text]
  • IRS2 Mutations Linked to Invasion in Pleomorphic Invasive Lobular Carcinoma
    IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma Sha Zhu, … , Dina Kandil, Leslie M. Shaw JCI Insight. 2018;3(8):e97398. https://doi.org/10.1172/jci.insight.97398. Research Article Oncology Pleomorphic invasive lobular carcinoma (PILC) is an aggressive variant of invasive lobular breast cancer that is associated with poor clinical outcomes. Limited molecular data are available to explain the mechanistic basis for PILC behavior. To address this issue, targeted sequencing was performed to identify molecular alterations that define PILC. This sequencing analysis identified genes that distinguish PILC from classic ILC and invasive ductal carcinoma by the incidence of their genomic changes. In particular, insulin receptor substrate 2 (IRS2) is recurrently mutated in PILC, and pathway analysis reveals a role for the insulin receptor (IR)/insulin-like growth factor-1 receptor (IGF1R)/IRS2 signaling pathway in PILC. IRS2 mutations identified in PILC enhance invasion, revealing a role for this signaling adaptor in the aggressive nature of PILC. Find the latest version: https://jci.me/97398/pdf RESEARCH ARTICLE IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma Sha Zhu,1 B. Marie Ward,2 Jun Yu,1 Asia N. Matthew-Onabanjo,1 Jenny Janusis,1 Chung-Cheng Hsieh,1 Keith Tomaszewicz,3 Lloyd Hutchinson,3 Lihua Julie Zhu,1,4,5 Dina Kandil,3 and Leslie M. Shaw1 1Department of Molecular, Cell and Cancer Biology, 2Department of Surgery, 3Department of Pathology, 4Department of Molecular Medicine, and 5Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. Pleomorphic invasive lobular carcinoma (PILC) is an aggressive variant of invasive lobular breast cancer that is associated with poor clinical outcomes.
    [Show full text]
  • Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: a Canonical Pathway
    Lipid related genes altered in NASH connect inflammation in liver pathogenesis progression to HCC: a canonical pathway Christophe Desterke1, Franck Chiappini2* 1 Inserm, U935, Villejuif, F-94800, France 2 Cell Growth and Tissue Repair (CRRET) Laboratory, Université Paris-Est Créteil (UPEC), EA 4397 / ERL CNRS 9215, F-94010, Créteil, France. Corresponding author: *Franck Chiappini. Laboratoire du CRRET (Croissance, Réparation et Régénération Tissulaires), Université Paris-Est Créteil, 61 avenue du Général de Gaulle F- 94010, Créteil Cedex, Val de Marne, France. Email address: [email protected]; Tel: +33(0)145177080; Fax: +33(0)145171816 Supplementary Information Supplementary Datasets Table S1: Text-mining list of genes associated in PubMed literature with lipid related keywords. Supplementary Datasets Table S2: Expression fold change of lipid related genes found differentially expressed between NASH and healthy obese liver samples. Supplementary Datasets Table S3: Liver as principal filter for prioritization of lipid related genes found differentially expressed in NASH. Supplementary Datasets Table S4: Gene prioritization secondary filters (immunological, inflammation, liver pathogenesis progression) table found with lipid related genes differentially expressed in NASH. Supplementary Datasets Table S5: Identification of protein partners of YWHAZ gene using InnateDB database. Supplementary Datasets Table S1: Text-mining list of genes associated in PubMed literature with lipid related keywords. Ranking of "lipidic" textmining Gene symbol
    [Show full text]
  • Costimulation of Resting B Lymphocytes Alters the IL-4
    Cell Research, (2001); 11(1):44-54 Costimulation of resting B lymphocytes alters the IL-4-activated IRS2 signaling pathway in a STAT6 independent manner: impli- cations for cell survival and proliferation ZAMORANO JOSE*, ANN E KELLY, JONATHAN AUSTRIAN, HELEN Y WANG, ACHSAH D KEEGAN** Department of Immunology, Jerome Holland Labs, American Red Cross, Rockville, MD, USA ABSTRACT IL-4 is an important B cell survival and growth factor. IL-4 induced the tyrosine phosphorylation of IRS2 in resting B lymphocytes and in LPS- or CD40L-activated blasts. Phosphorylated IRS2 coprecipitated with the p85 subunit of PI 3' kinase in both resting and activated cells. By contrast, association of phosphory- lated IRS2 with GRB2 was not detected in resting B cells after IL-4 treatment although both proteins were expressed. However, IL-4 induced association of IRS2 with GRB2 in B cell blasts. The pattern of IL-4- induced recruitment of p85 and GRB2 to IRS2 observed in B cells derived from STAT6 null mice was identical to that observed for normal mice. While IL-4 alone does not induce activation of MEK, a MEK1 inhibitor suppressed the IL-4-induced proliferative response of LPS-activated B cell blasts. These results demonstrate that costimulation of splenic B cells alters IL-4-induced signal transduction independent of STAT6 leading to proliferation. Furthermore, proliferation induced by IL-4 in LPS-activated blasts is de- pendent upon the MAP kinase pathway. Key words: B lymphocytes, IL-4, survival, proliferation. INTRODUCTION Interleukin-4 (IL-4), a cytokine produced by T The inappropriate enhancement of lymphocyte cells, mast cells, and basophils, has profound ef- survival due to a block in programmed cell death fects on the growth and differentiation of B and T and/or an enhancement of entry into the cell cycle lymphocytes[3].
    [Show full text]
  • Neuronal Insulin Receptor Substrate 2 (IRS2) Expression Is Regulated by ZBP89 and SP1 Binding to the IRS2 Promoter
    199 Neuronal insulin receptor substrate 2 (IRS2) expression is regulated by ZBP89 and SP1 binding to the IRS2 promoter Michael Udelhoven, Mareike Pasieka, Uschi Leeser, Wilhelm Krone and Markus Schubert Department of Internal Medicine II, Center for Molecular Medicine Cologne (CMMC) and Cologne Excellence Cluster on Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany (Correspondence should be addressed to M Schubert; Email: [email protected]) Abstract Since neuronal insulin receptor substrate 2 (IRS2)-mediated phosphoinositide-3-kinase (PI3K) via increased ZBP89 binding signals coordinate key processes in rodent physiology such as to the promoter. Serum starvation caused increased SP1 binding food intake, fertility, longevity, and aging-related behavior, we at one specific SP1 site and decreased binding to another, analyzed the mechanisms of neuronal IRS2 expression in proving a regulatory interaction between the different binding neuroblastoma (SHSY5Y) and hypothalamic (GT1-7) cell lines. sites within this promoter cassette to tightly control IRS2 Using dual luciferase reporter assays and IRS2 promoter expression. Mutants containing all the possible combinations of deletion constructs, we identified a regulatory cassette within one, two, three, or all the four SP1 binding sites of the IRS2 the IRS2 promoter between K779 and K679 bp from the promoter revealed that SP1 binding to one particular site is translational start which is responsible for w50% of neuronal most important for promoter activation. Stable downregulation IRS2 promoter activity.Chromatin immunoprecipitation assays of ZBP89 using siRNA substantially increased IRS2 mRNA and electromobility shift assay revealed four overlapping and protein expression.
    [Show full text]
  • A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre- Clinical Discoveries
    Cancers 2019 S1 of S18 Supplementary Materials: A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre- Clinical Discoveries Danilo Fiore, Luca Vincenzo Cappelli, Paul Zumbo, Jude M. Phillip, Zhaoqi Liu, Shuhua Cheng, Liron Yoffe, Paola Ghione, Federica Di Maggio, Ahmet Dogan, Inna Khodos, Elisa de Stanchina, Joseph Casano, Clarisse Kayembe, Wayne Tam, Doron Betel, Robin Foa’, Leandro Cerchietti, Raul Rabadan, Steven Horwitz, David M. Weinstock and Giorgio Inghirami A B C Figure S1. (A) Histology micrografts on IL89 PDTX show overall similarity between T1 T3 and T7 passages (upper panels). Immunohistochemical stains with the indicated antibodies (anti-CD3, anti- CD25 and anti-CD8 [x20]) (lower panels). (B) Flow cytometry panel comprehensive of the most represented surface T-cell lymphoma markers, including: CD2, CD3, CD4, CD5, CD8, CD16, CD25, CD30, CD56, TCRab, TCRgd. IL89 PDTX passage T3 is here depicted for illustration purposes. (C) Analysis of the TCR gamma specific rearrangement clonality in IL89 diagnostic sample and correspondent PDTX after 1 and 5 passages (T1 and T5). A WT Primary p.G1097D IL89 T1 p.G1097D IL89 T5 p.G1097D IL89 cell line B Figure S2. (A) Sanger sequencing confirms the presence of the JAK1 p.G1097D mutation in IL89 PDTX samples and in the cell line, but the mutation is undetectable in the primary due to the low sensitivity of the technique. (B) Manual backtracking of mutations in the primary tumor using deep sequencing data allowed for the identification of several hits at a very low VAF compared to the PDTX-T5. A B IL89 CTRL 30 CTRL Ruxoli?nib S 20 M Ruxoli?nib A R G 10 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 1 1 1 1 1 WEEKS AFTER ENGRAFTMENT Figure S3.
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Prolonged Elimination of Negative Feedback Control Mechanisms Along the Insulin Signalling Pathway Impairs  Cell Function in Vivo
    Page 1 of 39 Diabetes 1 Prolonged Elimination of Negative Feedback Control Mechanisms Along the Insulin Signalling Pathway Impairs Cell Function In Vivo Roi Isaac, Yaron Vinik, Sigalit Boura-Halfon, Lydia Farack, Sarina Streim, Eytan Elhanany, Zvi Kam, and Yehiel Zick Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel Running Title: Effects of IRS2 on -cell functionin vivo Corresponding Author: Yehiel Zick, Department of Molecular Cell Biology, Weizmann Institute of Science Rehovot,76100 Israel; Tel: +972-89-342380; Fax: +972-89-344125; e-mail: [email protected] Words : 3,999 Figures: 8 Diabetes Publish Ahead of Print, published online April 19, 2017 Page 2 of 39 Diabetes Abstract 2 Cellular stress and pro-inflammatory cytokines induce phosphorylation of insulin receptor substrate (IRS) proteins at Ser sites that inhibit insulin and IGF-1 signalling. We therefore examined the effects of mutation of five ‘inhibitory’Ser phosphorylation sitesonIRS2 function in transgenic mice that overexpress, selectively in pancreatic cells, either wild-type (WT) or a mutated IRS2 protein (IRS25A).Islets size, number, and mRNA levels of catalase and superoxide dismutase, were increased, while those of nitric oxide synthase were decreased in 7-10 weeks old IRS25A-β micecompared to IRS2WT-β mice. However, glucose homeostasis and insulin secretion in IRS25A-β mice were impaired, when compared to IRS2WT-β mice or to non-transgenic animals. This was associated withreduced mRNA levels of Glut2 and islet cell transcription factors such as Nkx6.1 and MafA.Similarly, components mediating the unfolded protein response (UPR) were decreased in islets of IRS25A-β micein accordance with their decreased insulin secretion.The beneficial effects of IRS25Aon cell proliferation and cell transcription factorswere evident only in 5-8 days old mice.These findings suggest that elimination of ‘inhibitory’ Ser phosphorylation sites of IRS2exertsshort-term beneficial effectsin vivo, howevertheir sustained elimination leads to impaired cell function.
    [Show full text]
  • Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes
    Biosci. Biotechnol. Biochem., 77 (3), 566–571, 2013 Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes y Tomoji ONO,1;2; Chikako FUJISAKI,1 Yasuharu ISHIHARA,1 Keiko IKOMA,1;2 Satoru MORISHITA,1;3 Michiaki MURAKOSHI,1;4 Keikichi SUGIYAMA,1;5 Hisanori KATO,3 Kazuo MIYASHITA,6 Toshihide YOSHIDA,4;7 and Hoyoku NISHINO4;5 1Research and Development Headquarters, Lion Corporation, 100 Tajima, Odawara, Kanagawa 256-0811, Japan 2Department of Supramolecular Biology, Graduate School of Nanobioscience, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan 3Food for Life, Organization for Interdisciplinary Research Projects, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan 4Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto 602-8566, Japan 5Research Organization of Science and Engineering, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan 6Department of Marine Bioresources Chemistry, Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minatocho, Hakodate, Hokkaido 041-8611, Japan 7Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu, Nakagyou-ku, Kyoto 604-8845, Japan Received October 22, 2012; Accepted November 26, 2012; Online Publication, March 7, 2013 [doi:10.1271/bbb.120817] Lactoferrin (LF) is a multifunctional glycoprotein resistance, high blood pressure, and dyslipidemia. To found in mammalian milk. We have shown in a previous prevent progression of metabolic syndrome, lifestyle clinical study that enteric-coated bovine LF tablets habits must be improved to achieve a balance between decreased visceral fat accumulation. To address the energy intake and consumption. In addition, the use of underlying mechanism, we conducted in vitro studies specific food factors as helpful supplements is attracting and revealed the anti-adipogenic action of LF in pre- increasing attention.
    [Show full text]
  • BIOINFORMATICS DISCOVERY NOTE Doi:10.1093/Bioinformatics/Btu493
    Vol. 30 no. 21 2014, pages 2999–3003 BIOINFORMATICS DISCOVERY NOTE doi:10.1093/bioinformatics/btu493 Systems biology Advance Access publication July 26, 2014 Comparison of the mammalian insulin signalling pathway to invertebrates in the context of FOXO-mediated ageing Irene Papatheodorou1,2,*,y, Rudolfs Petrovs1 and Janet M. Thornton1,* 1EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK, 2Institute of Healthy Ageing and Department of Genetics Evolution and Environment, University College London, London WC1E 6BT, UK Downloaded from https://academic.oup.com/bioinformatics/article/30/21/2999/2422239 by guest on 24 September 2021 Associate Editor: Igor Jurisica ABSTRACT species via the transcription factor FOXO (Kenyon, 2011). Motivation: A large number of experimental studies on ageing focus The mechanisms by which ‘FOXO increased activity’ leads to on the effects of genetic perturbations of the insulin/insulin-like growth lifespan extension are still unclear. However, it is thought that factor signalling pathway (IIS) on lifespan. Short-lived invertebrate la- lifespan extension is achieved through cell-cycle arrest by FOXO boratory model organisms are extensively used to quickly identify in the absence of insulin signalling (van der Horst and Burgering, ageing-related genes and pathways. It is important to extrapolate 2007). In addition, identification of FOXO transcriptional tar- this knowledge to longer lived mammalian organisms, such as gets has revealed a second tier of transcription factors regulating mouse and eventually human, where such analyses are difficult or a variety of downstream responses (Alic et al., 2011). Ageing via impossible to perform. Computational tools are needed to integrate the IIS pathway has been intensively studied at the level of in- and manipulate pathway knowledge in different species.
    [Show full text]
  • Small Molecule Protein–Protein Interaction Inhibitors As CNS Therapeutic Agents: Current Progress and Future Hurdles
    Neuropsychopharmacology REVIEWS (2009) 34, 126–141 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $30.00 ............................................................................................................................................................... REVIEW 126 www.neuropsychopharmacology.org Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles 1 ,1,2,3 Levi L Blazer and Richard R Neubig* 1Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; 3Center for Chemical Genomics, University of Michigan Medical School, Ann Arbor, MI, USA Protein–protein interactions are a crucial element in cellular function. The wealth of information currently available on intracellular-signaling pathways has led many to appreciate the untapped pool of potential drug targets that reside downstream of the commonly targeted receptors. Over the last two decades, there has been significant interest in developing therapeutics and chemical probes that inhibit specific protein–protein interactions. Although it has been a challenge to develop small molecules that are capable of occluding the large, often relatively featureless protein–protein interaction interface, there are increasing numbers of examples of small molecules that function in this manner with reasonable potency. This article will highlight the current progress in the development of small
    [Show full text]